Compare CLST & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | PDSB |
|---|---|---|
| Founded | 1922 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 62.0M |
| IPO Year | 2021 | 2015 |
| Metric | CLST | PDSB |
|---|---|---|
| Price | $16.26 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 3.5K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.79 | 28.16 |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $107.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.02 | $0.51 |
| 52 Week High | $18.16 | $1.67 |
| Indicator | CLST | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 66.85 | 40.64 |
| Support Level | $15.90 | $0.57 |
| Resistance Level | $16.98 | $1.12 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 69.00 | 10.28 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.